We suggest that clinical trials be conducted with HIV/AIDS patients to achieve post-ART-mediated minimal detectable virus loads in vivo and subsequent administration of ISG15 in combination with LRA-prodrug PKCMs alternating with ART. The gene discussed is ISG15; the disease is AIDS.